| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/22/2011 | EP2336368A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/22/2011 | EP2336322A1 Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 06/22/2011 | EP2336190A2 Anti-VEGF antibodies |
| 06/22/2011 | EP2336187A2 Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations |
| 06/22/2011 | EP2336185A1 Anti- alpha v beta 6 antibodies |
| 06/22/2011 | EP2336180A1 Antibody specifically binding to angiopoietin-2 and use thereof |
| 06/22/2011 | EP2336179A1 Stabilized single domain antibodies |
| 06/22/2011 | EP2336171A1 Novel targets for the treatment of proliferative diseases |
| 06/22/2011 | EP2336167A1 MHC molecule constructs and their uses for diagnosis and therapy |
| 06/22/2011 | EP2336166A1 Compositions that inhibit proliferation of cancer cells |
| 06/22/2011 | EP2336144A1 Esterified alpha-galactosylceramide |
| 06/22/2011 | EP2336141A2 Phosphoramidate alkylator prodrugs |
| 06/22/2011 | EP2336138A2 Prodrugs of HIV protease inhibitors |
| 06/22/2011 | EP2336133A1 Purine analogs having HSP90-inhibiting activity |
| 06/22/2011 | EP2336132A1 Morpholinopurine derivative |
| 06/22/2011 | EP2336123A2 Heterocyclic compound as protein kinase inhibitor |
| 06/22/2011 | EP2336122A1 1-pyrimidinyl- or 1-pyridinyl-2-amino benzimidazole derivatives and related compounds as inhibitors of protein kinases for the treatment of cancer |
| 06/22/2011 | EP2336120A1 Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| 06/22/2011 | EP2336111A1 Heterocyclic inhibitors of p38 |
| 06/22/2011 | EP2336108A1 Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses |
| 06/22/2011 | EP2336107A2 Proton pump inhibitors |
| 06/22/2011 | EP2335736A1 Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (gnrh) as immunogen |
| 06/22/2011 | EP2335733A1 Specific therapy using integrin ligands for treating cancer |
| 06/22/2011 | EP2335729A2 Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| 06/22/2011 | EP2335728A1 Specific binding proteins and uses thereof |
| 06/22/2011 | EP2335706A1 Preparation of thioarabinofuranosyl compounds and use thereof |
| 06/22/2011 | EP2335702A1 Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent |
| 06/22/2011 | EP2334826A2 Method of detection and diagnosis of oral and nasopharyngeal cancers |
| 06/22/2011 | EP2334791A1 Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase |
| 06/22/2011 | EP2334789A1 Breast cancer related gene rqcd1 |
| 06/22/2011 | EP2334704A1 Monoclonal antibodies specific for pancreatic neoplasia cells |
| 06/22/2011 | EP2334703A1 Compositions and methods for detecting tlr3 |
| 06/22/2011 | EP2334686A2 Cortistatin analogues and syntheses therof |
| 06/22/2011 | EP2334683A1 Saturated bicyclic heterocyclic derivatives as smo antagonists |
| 06/22/2011 | EP2334658A2 Ortho-aminoanilides for the treatment of cancer |
| 06/22/2011 | EP2334642A2 Simplified one-pot synthesis of [18f]sfb for radiolabeling |
| 06/22/2011 | EP2334380A1 Anti-ligands molecules and biological applications |
| 06/22/2011 | EP2334331A1 Anti-notch2 antibodies and methods of use |
| 06/22/2011 | EP2334303A1 Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer |
| 06/22/2011 | EP2334301A1 Macrocyclics pyrimidines as aurora kinase inhibitors |
| 06/22/2011 | EP2334293A2 Compositions comprising polyhydroxyltate fatty alcohol derivatives and the therapeutic uses |
| 06/22/2011 | EP2334292A1 Method of determining a phosphorus binder dosage for a dialysis patient |
| 06/22/2011 | EP2260026B1 Quinazolinone derivatives as tubulin polymerization inhibitors |
| 06/22/2011 | EP2231662B1 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| 06/22/2011 | EP2227240B1 Parvovirus cancer therapy and combination with chemotherapy |
| 06/22/2011 | EP2132228B1 Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| 06/22/2011 | EP1616856B1 Novel transcriptional factor, process for producing the same and use thereof |
| 06/22/2011 | EP1324771B1 Therapeutic and tolerance inducing antibodies |
| 06/22/2011 | EP1290161B1 METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi |
| 06/22/2011 | EP1207876B1 Use of a modulator which acts on a growth factor precursor in order to inhibit growth factor precursor processing |
| 06/22/2011 | EP1204683B1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 06/22/2011 | EP1109827B1 Bioactive peptides |
| 06/22/2011 | DE102009058769A1 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung Temperature-dependent activation of catalytic nucleic acids for controlled drug release |
| 06/22/2011 | CN1891714B Ligand for herpes simplex virus entry mediator and methods of use |
| 06/22/2011 | CN1845734B Benzimidazole derivatives and their use as protein kinases inhibitors |
| 06/22/2011 | CN1809570B [1,2,4 ]triazolo [1,5-a]pyrimidin-2-ylurea derivative and use thereof |
| 06/22/2011 | CN1701073B Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 06/22/2011 | CN1596314B Method of determining a chemotherapeutic regimen based on ercc1 and ts expression |
| 06/22/2011 | CN1560078B Tumor antigen based on products of the tumor suppressor gene WT1 |
| 06/22/2011 | CN1447819B Human CYR 61 |
| 06/22/2011 | CN102105487A CRKL targeting peptides |
| 06/22/2011 | CN102105474A Purine PI3K inhibitor compounds and methods of use |
| 06/22/2011 | CN102105462A Amidophenoxyindazoles useful as inhibitors of C-MET |
| 06/22/2011 | CN102105459A 3,4-diarylpyrazoles as protein kinase inhibitors |
| 06/22/2011 | CN102105457A 5-demethoxyfumagillol and derivatives thereof |
| 06/22/2011 | CN102105449A Arylsulfonamide compounds, compositions and methods of use |
| 06/22/2011 | CN102105448A Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states |
| 06/22/2011 | CN102105162A The use of Wnt5-a peptide derivates for the treatment of melanoma and gastric cancer |
| 06/22/2011 | CN102105161A Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor |
| 06/22/2011 | CN102105152A Therapeutic combination comprising a cdks inhibitor and an antineoplastic agent |
| 06/22/2011 | CN102105148A Therapeutic combination comprising an AURORA kinase inhibitor and antiproliferative agents |
| 06/22/2011 | CN102105147A Therapeutic combination comprising an AURORA kinase inhibitor and an antineoplastic agent |
| 06/22/2011 | CN102102102A Novel application of hsa-miR-185 |
| 06/22/2011 | CN102102101A SiRNA for inhibiting expression of Plk1 and use thereof |
| 06/22/2011 | CN102101888A Novel polypeptide for resisting tumors caused by EB (Epstein-Barr) viruses, and application and preparation method thereof |
| 06/22/2011 | CN102101886A Variable-conformation recombinant interferon crystal, and three-dimensional structure and use thereof |
| 06/22/2011 | CN102101885A Human interleukin-II mutant of low-inductivity suppressor T cells and use thereof |
| 06/22/2011 | CN102101879A Arenobufagin space isomer compound and preparation and application thereof |
| 06/22/2011 | CN102101878A Hellebore petunidin space isomer compound and preparation and application thereof |
| 06/22/2011 | CN102101874A Novel di(cyclopentadienyl)iron pyrazol copper and silver complexes and use thereof |
| 06/22/2011 | CN102101866A Halogenated derivatives of staurosporine, and preparation method thereof and use thereof |
| 06/22/2011 | CN102101863A Novel epoxy thiazone compounds and preparation method and application thereof |
| 06/22/2011 | CN102100916A Freeze-drying liposome and preparation method and application thereof |
| 06/22/2011 | CN102100915A Chlorambucil multi-targeting medicine carrying system and preparation method and application thereof |
| 06/22/2011 | CN102100914A Artificial oil body carrier for targeted therapy of mastocarcinoma as well as preparation method and application thereof |
| 06/22/2011 | CN102100897A Preparation technology and preparation method of novel integrative Erchen decoction dosage form |
| 06/22/2011 | CN102100894A Preparation technology of new integrative formulation of free wanderer powder and production method thereof |
| 06/22/2011 | CN102100892A Preparation technology and production method of integrated Xiaojianzhong decoction novel dosage form |
| 06/22/2011 | CN102100885A Preparation technology and production method of integrated minor bupleurum decoction novel dosage form |
| 06/22/2011 | CN102100876A Medicament for treating hysteromyoma |
| 06/22/2011 | CN102100875A Process method for microwave assistant supercritical extraction of active ingredients of curcuma |
| 06/22/2011 | CN102100836A Medicinal composition for treating tumors, preparation method thereof and application thereof |
| 06/22/2011 | CN102100765A Processing technique of peach kernels |
| 06/22/2011 | CN102100741A Total tanshinone composite preparation |
| 06/22/2011 | CN102100736A Method for simultaneously extracting water-soluble and lipid-soluble effective components in traditional Chinese medicine salvia miltiorrhiza bunge |
| 06/22/2011 | CN102100725A Preparation technology of extracting total alkaloid extraction from Gansu whin |
| 06/22/2011 | CN102100724A Method for processing eucommia ulmoides bark and preparing handicraft by eucommia ulmoides branch and root |
| 06/22/2011 | CN102100710A Fermentation processing method for ginseng and research and development of related products thereof |
| 06/22/2011 | CN102100694A Application of tetrahydropalmatine enantiomers in preparation of P-glycoprotein inhibitor |
| 06/22/2011 | CN102100692A Prenylflavanone compound and use thereof in preparation of anti-tumor medicaments |